ABSTRACT

This study explores how the β-blocker nebivolol inhibits pro-inflammatory IL-17, potentially through the Th17/Treg balance theory (Gonczi et al., 2017, 2021, 2023; Lee, 2018). This theory suggests that inflammatory and anti-inflammatory responses balance each other to maintain good health (Lee, 2018). Increased anti-inflammatory IL-10 secretion may play a role in this regulatory process (Gonczi et al., 2017; Lee, 2018). Peripheral blood mononuclear cells (PBMCs) were isolated from healthy participants, and memory CD4+T cells were purified. Cells were cultured under various conditions, including activation with antibody multicomplex and nebivolol treatment, followed by enzyme-linked immunofluorescent assay (ELISA) to measure IL-10 secretion levels. The data indicate that nebivolol treatment did not result in a significant increase in IL-10 secretion compared to activated controls, suggesting alternative pathways for nebivolol’s effect on IL-17A inhibition in T cells beyond IL-10 regulation. Limitations include variability in Treg proportions in memory CD4+ T cells and incubation time differences for peak IL-10 secretion. Future research should implement flow cytometry for Treg identification and refine IL-10 secretion protocols specific to Tregs to enhance understanding of immune regulation and potential therapeutic applications.